Swiss biotech company Alentis Therapeutics has successfully closed a $181.4 million oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors. The financing will support the company to develop a deep pipeline of
Swiss biotech company Alentis Therapeutics has successfully closed a $181.4 million oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors. The financing will support the company to develop a deep pipeline of